The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Genetic abnormalities for detecting patients at risk of AML
In this interview, Prof. Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, suggests that various parameters should be considered when monitoring patients before they progress to acute myeloid leukemia (AML), such as anemia and fibrosis. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Verstovsek emphasises that genetic abnormalities can be detected in healthy people without the disease, so various other factors such as the bone marrow environment should be considered when making informed diagnostic and therapeutic decisions of myeloproliferative disorders.
